UK – ICR welcomes new advanced prostate cancer treatment guideline

The Institute of Cancer Research, London, has welcomed approval of targeted hormone therapies enzalutamide and abiraterone as first-line NHS treatments for men with advanced prostate cancer.

Standard treatment for men first diagnosed with advanced prostate cancer is hormone therapy – either as monotherapy or together with docetaxel chemotherapy.

Docetaxel is generally given as six three-weekly infusions in hospital and can significantly weaken patients’ immune system and cause inflammation of the lungs – putting men at risk during the current COVID-19 pandemic, ICR experts note…